两种聚腺苷二磷酸核糖聚合酶1抑制剂对人肝癌细胞株HepG2增殖和凋亡的影响

杜森荣; 毛小荣; 肖萍; 陈红

doi:10.3969/j.issn.1001-5256.2015.06.027

两种聚腺苷二磷酸核糖聚合酶1抑制剂对人肝癌细胞株HepG2增殖和凋亡的影响

DOI: 10.3969/j.issn.1001-5256.2015.06.027

1. 兰州大学第一临床医学院
2. 兰州大学第一医院传染科

基金项目:

甘肃省4316技术研究与开发专项计划项目(1305TCYA023)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1976
- HTML全文浏览量: 16
- PDF下载量: 516
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2

Research funding:

摘要

摘要:
目的观察聚腺苷二磷酸核糖聚合酶（PARP）-1抑制剂AG-014699和AZD2281对人肝癌细胞株Hep G2细胞抑制作用和凋亡,初步探讨PARP-1抑制剂诱导Hep G2细胞凋亡的机制,为肝癌提供一种新的治疗靶点。方法 MTT实验观察不同浓度的AG-014699和AZD2281对Hep G2细胞增殖的影响,用流式细胞术检测Hep G2细胞凋亡率;Western Blot法检测casepase3和casepase8蛋白表达水平。组间比较采用t检验。结果 AG014699和AZD2281均有抑制Hep G2细胞增殖的作用,且具有时间和浓度依赖性,但Hep G2细胞对两种PARP-1抑制剂的敏感性不同,用MTT法检测48 h AG-014699和AZD2281的IC50分别约为20、400μmol/L。因AZD2281不敏感,未做流式细胞术和Western Blot法检测细胞凋亡。用10、30、50μmol/L的AG-014699能诱导Hep G2细胞凋亡,48 h时凋亡率最高达（31.00±2.13）%,明显高于对照组（0.900±0.013）%,二者差异有统计学意义（P<0.0...
- 肝肿瘤 /
- 聚ADP核糖聚合酶类 /
- 酶抑制剂 /
- Hep G2细胞 /
- 细胞增殖 /
- 细胞凋亡
Abstract:
Objective To observe the inhibitory and pro- apoptotic effects of two poly( ADP- ribose) polymerase( PARP- 1) inhibitors,AG- 014699 and AZD2281,on human hepatoma Hep G2 cells and preliminarily explore the mechanism by which AG- 014699 induces Hep G2 cell apoptosis,and to provide a new therapeutic target for hepatoma. Methods The effects of different concentrations of AG-014699 and AZD2281 on Hep G2 cell proliferation were determined by MTT assay. The cell apoptosis rate was measured by flow cytometry.The expression levels of caspase- 3 and caspase- 8 were measured by Western Blot. Inter- group comparison was made by t test. Results Both AG- 014699 and AZD2281 suppressed Hep G2 cell proliferation in a time- and dose- dependent manner. However,the sensitivity of Hep G2 cells to the two PARP- 1 inhibitors was different. The half- maximal inhibitory concentrations of AG- 014699 and AZD2281 at48 h determined by MTT assay were about 20 μmol / L and 400 μmol / L,respectively. Flow cytometry and Western blot were not used to evaluate the apoptosis of Hep G2 cells exposed to AZD2281 to which these cells were not sensitive. Hep G2 cell apoptosis could be induced by10,30,and 50 μmol / L AG- 014699,and the highest apoptosis rate at 48 h was significantly higher than that of the control group( 31. 00% ± 2. 13% vs 0. 9% ± 0. 013%,P < 0. 01). Compared with those in the control group,the protein levels of caspase- 3 and caspase- 8 in Hep G2 cells after 48- h exposure to 30,and 50 μmol / L AG- 014699 increased. Conclusion The two PARP- 1 inhibitors AG- 014699 and AZD2281 can inhibit the proliferation of Hep G2 cells,which showed different sensitivities to the two inhibitors. AG-014699 can induce Hep G2 cell apoptosis by up- regulating the protein expression of caspase- 3 and caspase- 8.
- liver neoplasms /
- poly(ADP-ribose) polymerases /
- enzyme inhibitors /
- Hep G2 cell line /
- cell proliferation /
- apoptosis

HTML全文

参考文献(16)

[1]LAFARO KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17.

[2]WESIERSKA-GADEK J,HEINZL S.Interactions between ataxia telangiectasia mutated kinase inhibition,poly(adp-ribose)polymerase-1 inhibition and brca1 status in breast cancer cells[J].J Cancer Prev,2014,19(2):125-136.

[3]DAVIDSON D,WANG Y,ALOYZ R,et al.The parp inhibitor abt-888 synergizes irinotecan treatment of colon cancer cell lines[J].Invest New Drugs,2013,31(2):461-468.

[4]DONG Y,BEY EA,LI LS,et al.Prostate cancer radiosensitization through poly(adp-ribose)polymerase-1 hyperactivation[J].Cancer Res,2010,70(20):8088-8096.

[5]LEE HJ,YOON C,SCHMIDT B,et al.Combining parp-1 inhibition and radiation in ewing sarcoma results in lethal DNA damage[J].Mol Cancer Ther,2013,12(11):2591-2600.

[6]LUO Q,LI Y,DENG J,et al.PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair[J].Chem Biol Interact,2015,226:12-22.

[7]CLAMP A,JAYSON G.PARP inhibitors in BRCA mutation-associated ovarian cancer[J].Lancet Oncol,2014,349:859-866.

[8]ZHU HL,WU WQ,DUAN XL,et al.Effect of PARP-1 inhibitor5-AIQ combined with Etoposide on the proliferation of prostate cancer cell line PC3[J].Hainan Med J,2013,24(7):937-939.(in Chinese)朱寒亮,吴文起,段小鹿,等.PARP-1抑制剂5-AIQ联合依托泊苷对PC3细胞增殖的影响[J].海南医学,2013,24(7):937-939.

[9]LINN SC,van'T VEER LJ.Clinical relevance of the triple-negative breast cancer concept:Genetic basis and clinical utility of the concept[J].Eur J Cancer,2009,45(Suppl 1):11-26.

[10]MUOZ-GMEZ JA1,LPEZ VIOTA J,BARRIENTOS A,et al.Synergistic cytotoxicity of the poly(adp-ribose)polymerase inhibitor abt-888 and temozolomide in dual-drug targeted magnetic nanoparticles[J].Liver Int,2015,35(4):1430-1441.

[11]LI XM,XU HD,LIN MN,et al.DNA damage:a double-edge sword in tumor and cellular senescence[J].Chin J Cell Biol,2013,35(2):134-140.(in Chinese)李小曼,徐红德,蔺美娜,等.DNA损伤修复反应的双刃剑效应在肿瘤与衰老发生发展中的作用[J].中国细胞生物学学报,2013,35(2):134-140.

[12]LI M,YU X.The role of poly(adp-ribosyl)ation in DNA damage response and cancer chemotherapy[J].Oncogene,2014.[Epub ahead of print]

[13]DOMAGALA P,HUZARSKI T,LUBINSKI J,et al.PARP-1 expression in breast cancer including brca1-associated,triple negative and basal-like tumors:possible implications for parp-1 inhibitor therapy[J].Breast Cancer Res Treat,2011,127(3):861-869.

[14]YANG X,NDAWULA C Jr,ZHOU H,et al.Jf-305,a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib[J].Oncol lett,2015,9(2):757-761.

[15]ZHOU X,HUANG ZY,CHEN XP,et al.Suppressive effect of poly(ADP-ribose)polymerase-1 inhibitor PJ34 on human hepatoma cell line Hep G2[J].World Chin J Dig,2007,15(16):1806-1809.(in Chinese)周欣,黄志勇,陈孝平,等.PARP-1抑制剂PJ34对人肝癌细胞株Hep G2的抑制作用[J].世界华人消化杂志,2007,15(16):1806-1809.

[16]ZHAO YC,GU Y.Research advances in cell apoptosis pathways[J].J Modern Med,2013,41(4):285-288.(in Chinese)赵彦超,顾耘.细胞凋亡通路研究进展[J].现代医学,2013,41(4):285-288.

施引文献

资源附件(0)

访问统计